Company
Headquarters: Shenyang, China
Employees: 1,102
CN¥12.83 Billion
CNY as of July 1, 2025
US$1.79 Billion
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $193.76 B |
| EssilorLuxottica SA | $128.90 B |
| Becton, Dickinson and Company | $50.81 B |
| Alcon Inc. | $44.33 B |
| HOYA Corp | $40.30 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥2.13 B |
| EBITDA | CN¥556.2 M |
| Gross Profit TTM | CN¥1.68 B |
| Profit Margin | 21.09% |
| Operating Margin | 34.59% |
| Quarterly Revenue Growth | 53.20% |
Shenyang Xingqi Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300573 wb_incandescent